BCL2 overexpression + MCL1 overexpression
|
Diffuse Large B Cell Lymphoma
|
BCL2 overexpression + MCL1 overexpression
|
Diffuse Large B Cell Lymphoma
|
ibrutinib + APG-2575 Sensitive: D – Preclinical
|
ibrutinib + APG-2575 Sensitive: D – Preclinical
|
BCL2 overexpression + MCL1 overexpression
|
Gastroesophageal Cancer
|
BCL2 overexpression + MCL1 overexpression
|
Gastroesophageal Cancer
|
AT 101 Sensitive: D – Preclinical
|
AT 101 Sensitive: D – Preclinical
|